Biohaven Pharmaceutical Holding Company Ltd. said two doses of an experimental treatment for acute migraine were effective in reducing headaches in a large study, sending the company’s shares up 8 percent.
The U.S. Food and Drug Administration approved Eli Lilly and Co.’s Reyvow, representing the first new class of acute migraine treatment approved by the regulatory agency in more than two decades.
